Berking, Ann-Cathrine http://orcid.org/0000-0003-2658-4211
Thiel, Christiane
Schiele, Miriam A.
Baumann, Christian
Kalisch, Raffael
Notzen, Swantje
Zwanzger, Peter
Pané-Farré, Christiane A.
Hamm, Alfons
Alpers, Georg W.
Fydrich, Thomas
Fehm, Lydia
Gerlach, Alexander L.
Straube, Benjamin
Kircher, Tilo
Rief, Winfried
Plag, Jens
Ströhle, Andreas
Lang, Thomas
Wittchen, Hans-Ulrich
Arolt, Volker
Romanos, Marcel
Pauli, Paul
Reif, Andreas
Deckert, Jürgen
Domschke, Katharina
Weber, Heike
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung
Article History
Received: 10 March 2020
Accepted: 8 May 2020
First Online: 29 May 2020
Compliance with ethical standards
:
: Over the last years, V. Arolt has been a member of the advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Eli Lilly, Janssen-Organon, Lundbeck, Otsuka, Servier, and Trommsdorff. He also received sponsorships for symposia and educational activities from Astra-Zeneca, Jansen-Organon, Lundbeck and Servier. K. Domschke is a member of the Janssen Pharmaceuticals, Inc. Steering Committee Neurosciences. R. Kalisch receives advisory honoraria from JoyVentures, Herzlia, Israel. T. Kircher received fees for educational programs from Janssen, Eli Lilly, Servier, Lundbeck, Bristol Myers Squibb, Pfizer and Astra-Zeneca. P. Pauli is a shareholder of a commercial company that develops virtual environment research systems for empirical studies in the field of psychology, psychiatry, and psychotherapy. A. Ströhle received research funding from Lundbeck, and speaker honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co, Lundbeck, Pfizer, Wyeth and UCB. He was a consultant for Actelion. Educational grants were given by the Boehringer Ingelheim Fonds, the Eli Lilly International Foundation, Janssen-Cilag, Pfizer and Eli Lilly & Co. H.-U. Wittchen has served as a general consultant (non-product related) for Pfizer, Lundbeck, Organon, Servier and EssexPharma and has received grant funding for his institution from Sanofi Aventis, Pfizer, Lundbeck, Novatis, Essex Pharma, Servier and Wyeth. These cooperations have no relevance to the work that is covered in the manuscript. The other authors declare no conflict of interest.